THIRD AMENDMENT TO DEVELOPMENT AND LICENSE AGREEMENTDevelopment and License Agreement • April 26th, 2018 • Alkermes Plc. • Pharmaceutical preparations • Delaware
THIS THIRD AMENDMENT TO DEVELOPMENT AND LICENSE AGREEMENT (the “Third Amendment”) is entered into effective as of March 20, 2018, (the “Third Amendment Effective Date”) between AMYLIN PHARMACEUTICALS, LLC, a Delaware limited liability corporation having a principal place of business at 9360 Towne Centre Drive, San Diego, CA 92121 (“Amylin”), and ALKERMES PHARMA IRELAND LIMITED, a private limited company incorporated in Ireland (registered number 448848) having a registered address at Connaught House, 1 Burlington Road, Dublin 4, Ireland (“APIL”) who is the successor-in-interest to ALKERMES CONTROLLED THERAPEUTICS INC. II (“ACTII”). Amylin and APIL are referred to herein collectively as “Parties” and individually as a “Party”.
February 28, 2018Employment Agreement • April 26th, 2018 • Alkermes Plc. • Pharmaceutical preparations
On behalf of Alkermes Inc., I am pleased to offer you the position of President and Chief Operating Officer, reporting to Richard Pops, CEO. This is a full-time exempt position located in Waltham, MA. While this position will be based principally in Waltham, MA, you understand and acknowledge that you may be required to travel from time to time for business purposes. In the event of any conflict between this offer letter (“Offer Letter”) and your Employment Agreement, dated as of March 2, 2018 (the “Employment Agreement”), this Offer Letter shall control and govern the rights and obligations of the Company and Executive. We acknowledge that you entered into your Employment Agreement prior to your countersignature of this Offer Letter.
AMENDMENT NO. 5 TO AMENDED AND RESTATED CREDIT AGREEMENTCredit Agreement • April 26th, 2018 • Alkermes Plc. • Pharmaceutical preparations • New York
THIS AMENDED AND RESTATED CREDIT AGREEMENT, dated as of September 16, 2011, as amended and restated on September 25, 2012, as amended by the Second Amendment on February 14, 2013, as further amended by the Third Amendment on May 22, 2013 and, as further amended by the Fourth Amendment on October 12, 2016 and as further amended by the Fifth Amendment on March 26, 2018, among ALKERMES, INC., a corporation organized under the laws of the Commonwealth of Pennsylvania (the “Borrower”), ALKERMES PLC, a company incorporated under the laws of the Republic of Ireland (registered number 498284) (“Holdings”), ALKERMES PHARMA IRELAND LIMITED, a private limited company organized under the laws of the Republic of Ireland (registered number 448848) and a wholly owned indirect subsidiary of Holdings (the “Intermediate Holdco”) and ALKERMES US HOLDINGS, INC., a Delaware corporation and a wholly owned subsidiary of Intermediate Holdco (“Holdco”), the several banks and other financial institutions or ent
LEASE BETWEEN PDM 900 UNIT, LLC AND ALKERMES, INC. FOR PREMISES LOCATED AT 900 WINTER STREET RESERVOIR WOODS, WALTHAM, MASSACHUSETTSLease Agreement • April 26th, 2018 • Alkermes Plc. • Pharmaceutical preparations • Massachusetts
LEASE dated as of March 23, 2018 (the “Effective Date”), by and between PDM 900 Unit, LLC, a Delaware limited liability company (hereinafter called “Landlord”), and Alkermes, Inc., a Pennsylvania corporation (hereinafter called “Tenant”).
